TARDBP

bit.bio Adds Two New Human Cell Products to Address the Translation Gap and Accelerate Research and Drug Discovery for Neurodegenerative Disease

Retrieved on: 
Thursday, September 29, 2022
Health, Neurology, Clinical Trials, Research, Science, Biotechnology, Motor neuron, TARDBP, Roivant Sciences, Central nervous system, IPSC, Culture, Memory, Neuron, FTD, Machine learning, University, Brain, AD, Disease, Microglia, CRISPR, Potency (pharmacology), Nobel Prize, Neurodegeneration, Series, Synthetic biology, Frontotemporal dementia, Language, Foresite Capital, Physiology, CEO, Technology, Biology, Atrophy, TAR, Cell, Frontotemporal lobar degeneration, Aggregation, Pathology, Founder, Drug development, Nobel Prize in Physiology or Medicine, Amyotrophic lateral sclerosis, Method, Research, ALS, Multimedia, Mutation, Drug discovery, HIV disease progression rates, Alzheimer's disease, Charles River Laboratories, Fine chemical, Vaccine, Pharmaceutical industry, Medical device, P2RY12, Tencent, Medicine

bit.bios latest cell products provide a scalable source of human cells and will enable scientists to study neurodegenerative diseases in a human context.

Key Points: 
  • bit.bios latest cell products provide a scalable source of human cells and will enable scientists to study neurodegenerative diseases in a human context.
  • The launch of two new cell products for research and drug discovery in neurodegenerative diseases validates our cell identity coding platforms ability to create and manufacture any human cell type consistently at scale.
  • Dr Farah Patell-Socha, VP Research Products at bit.bio, said:
    Human cells are key to disease research, drug discovery, and clinical translation.
  • These disease models offer a fast and easy-to-use system for investigations into the impact of gene function on disease progression.

Research Provides New Insight into ALS

Retrieved on: 
Wednesday, August 24, 2022
Science, Neurology, Biotechnology, Research, Pharmaceutical, Health, Clinical Trials, Other Health, Massachusetts General Hospital, SOD1, Harvard Medical School, Research, Neurotoxicity, Filtration, Cerebrospinal fluid, TARDBP, CSF, Mouse, Apolipoprotein B, C9orf72, Pathology, Hospital, Center, Neurology, International, Tisch, Neurodegeneration, MS, Fals, Spinal cord, Bacillus, Physical, ALS, Patient, Dentistry

Using an innovative experimental approach to deliver cerebrospinal fluid (CSF) from ALS patients, researchers developed a novel CSF-mediated mouse model to investigate pathophysiological mechanisms in different ALS subtypes.

Key Points: 
  • Using an innovative experimental approach to deliver cerebrospinal fluid (CSF) from ALS patients, researchers developed a novel CSF-mediated mouse model to investigate pathophysiological mechanisms in different ALS subtypes.
  • The impact of this research is potentially groundbreaking for patients with sporadic ALS, the predominant form of this devastating disease, said Dr. Saud A. Sadiq, Director and Chief Research Scientist at the Tisch MS Research Center of New York.
  • The patients were seen at the Sean M. Healey and AMG Center for ALS at Massachusetts General Hospital, as well as the Tisch MS Research Center of New Yorks Larry G. Gluck Division of ALS Research.
  • The mission of the Tisch Multiple Sclerosis Research Center of New York is to conduct groundbreaking medical research to ensure unparalleled care and positive outcomes for MS patients.

AC Immune Receives Competitive Target ALS Foundation Grant to Accelerate the Development of Proprietary Phosphorylated TDP-43 Immuno-assay

Retrieved on: 
Tuesday, December 15, 2020
Neurological disorders, Neurodegenerative disorders, TARDBP, Rare diseases, Amyotrophic lateral sclerosis, Assay

Our proprietary TDP-43 immuno-assays have shown great promise, with data highlighting their high sensitivity and large dynamic range for total and phosphorylated TDP-43.

Key Points: 
  • Our proprietary TDP-43 immuno-assays have shown great promise, with data highlighting their high sensitivity and large dynamic range for total and phosphorylated TDP-43.
  • This grant will accelerate the development AC Immunes anti-pTDP-43 immuno-assay to enable ex vivo diagnostic tests capable of identifying early stages of TDP-43 related diseases such as ALS.
  • Target ALS is a 501(c)(3) medical research foundation committed to the search for effective treatments for Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrigs disease.
  • We do this through our Target ALS Innovation Ecosystem, which facilitates unparalleled collaboration between researchers from academia and the pharma/biotech industry.

ProMIS Neurosciences’ Dr. Neil Cashman CSO, to Speak at 2020 ALS ONE Research Symposium

Retrieved on: 
Friday, October 30, 2020
Branches of biology, Nervous system, Neurological disorders, Rare diseases, TARDBP, Amyotrophic lateral sclerosis, Neurodegeneration, Intrabody, Protein aggregation, Gladstone Institutes, Genetics of amyotrophic lateral sclerosis

Our data demonstrate the unique ability of our antibody and intrabody candidates to selectively target toxic TDP-43 protein aggregates without affecting normal TDP-43, said Dr. Neil Cashman.

Key Points: 
  • Our data demonstrate the unique ability of our antibody and intrabody candidates to selectively target toxic TDP-43 protein aggregates without affecting normal TDP-43, said Dr. Neil Cashman.
  • They represent a promising first step in the eventual development of a safe and effective therapyfor ALS, FTD and other TDP-43-driven disorders.
  • We look forward to sharing our TDP-43 findings with the ALS research community dedicated to bringing us closer to an effective treatment for this devastating disease.
  • In neurodegenerative diseases, such as Alzheimers, ALS and Parkinsons disease, the DSEs are misfolded regions on toxic forms of otherwise normal proteins.

Competitive EU Grant Supports Collaboration to Accelerate Development of AC Immune's First-in-Class TDP-43 Diagnostic Agent

Retrieved on: 
Friday, October 9, 2020
Branches of biology, Biology, Neurological disorders, RTT, Neuroscience, TARDBP, Pathology, Precision medicine, Alzheimer's disease, Neurodegeneration, Amyotrophic lateral sclerosis, Benjamin Wolozin

Such a TDP-43 imaging agent may also enable the development of precision medicine approaches for Alzheimers disease (AD), where pathological aggregation of TDP-43 has emerged as an important co-pathology linked to disease severity.

Key Points: 
  • Such a TDP-43 imaging agent may also enable the development of precision medicine approaches for Alzheimers disease (AD), where pathological aggregation of TDP-43 has emerged as an important co-pathology linked to disease severity.
  • The rapid progress made in this program complements the ongoing development of our anti-TDP-43 antibody, which is on track to become the first such therapeutic to enter clinical development.
  • Through the continued advancement of this pipeline, AC Immune is taking a comprehensive approach towards the treatment of neurodegenerative diseases through precision medicine.
  • AC Immune SA is a Nasdaq-listed clinical-stage biopharmaceutical company, which aims to become a global leader in precision medicine for neurodegenerative diseases.

AC Immune Initiates IND-Enabling Studies for First-in-Class Antibody Targeting TDP-43 to Treat Neurodegeneration

Retrieved on: 
Monday, August 3, 2020
Immunology, Branches of biology, TARDBP, Antibody, Biology

The anti-TDP-43 antibody is the first therapeutic candidate shown to mitigate TDP-43 neuropathology in vivo and the Company plans to develop the antibody for the treatment of NeuroOrphan indications.

Key Points: 
  • The anti-TDP-43 antibody is the first therapeutic candidate shown to mitigate TDP-43 neuropathology in vivo and the Company plans to develop the antibody for the treatment of NeuroOrphan indications.
  • Initiation of IND-enabling studies for our first-in-class lead anti-TDP-43 antibody is a major step toward addressing pressing unmet need in NeuroOrphan indications.
  • The anti-TDP-43 antibody binds all forms of TDP-43 with high affinity and is the only antibody with reported in vivo activity.
  • AC Immune SA is a Nasdaq-listed clinical-stage biopharmaceutical company, which aims to become a global leader in precision medicine for neurodegenerative diseases.

ProMIS Neurosciences creates novel intrabodies for ALS, frontotemporal dementia and other neurodegenerative diseases

Retrieved on: 
Thursday, April 30, 2020
Branches of biology, Proteins, Neurological disorders, Organ systems, TARDBP, Neurodegeneration, Protein aggregation, Protein folding

Intrabodies are antibody therapies intended to work inside a cell, blocking toxic proteins, accelerating their degradation and preventing their spread to healthy cells.

Key Points: 
  • Intrabodies are antibody therapies intended to work inside a cell, blocking toxic proteins, accelerating their degradation and preventing their spread to healthy cells.
  • ProMIS has generated several highly selective intrabodies that bind to toxic TDP-43 protein aggregates within cells and promote their degradation without affecting normal TDP-43.
  • Weve used our platform to produce novel antibody candidates for several neurodegenerative diseases, including Parkinsons and Alzheimers.
  • In neurodegenerative diseases, such as Alzheimers, ALS and Parkinsons disease, the DSEs are misfolded regions on otherwise normal proteins.

ProMIS Neurosciences advances ALS program selectively targeting toxic form of TDP-43

Retrieved on: 
Wednesday, October 23, 2019
Branches of biology, Proteins, Biology, RTT, Alzheimer's disease, Dementia, Structural proteins, Amyloidosis, Amyloid beta, TARDBP, Aducanumab, Amyloid

ProMIS antibody candidates also show selective binding to the pathogenic, misfolded form of TDP-43 in post-mortem brain tissue from patients with FTD.

Key Points: 
  • ProMIS antibody candidates also show selective binding to the pathogenic, misfolded form of TDP-43 in post-mortem brain tissue from patients with FTD.
  • "The momentum behind each of our programs is palpable," said Elliot Goldstein, MD, ProMIS Neurosciences President and CEO.
  • "In the past 30 days, we've announced data advancing our development programs selectively targeting toxic misfolded proteins for treatment of Alzheimer's and Parkinson's disease and Multiple System Atrophy (MSA), ALS and FTD.
  • Our lead program, PMN310, offers sniper-like precision for the toxic, misfolded form of amyloid beta, a key feature that offers important potential advantages compared to aducanumab.

ProMIS Neurosciences Highlights Data for PMN310 at AAIC 2019

Retrieved on: 
Thursday, July 18, 2019
Neurological disorders, Brain, Nervous system, Dementia, Cognitive disorders, Frontal lobe, Temporal lobe, Frontotemporal dementia, Psychiatric diagnosis, Amyotrophic lateral sclerosis, TARDBP, Promis

Additionally, Chief Scientific Officer Dr. Neil Cashman presented data pertaining to the company's preclinical development program selectively targeting toxic forms of TDP43 for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).

Key Points: 
  • Additionally, Chief Scientific Officer Dr. Neil Cashman presented data pertaining to the company's preclinical development program selectively targeting toxic forms of TDP43 for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).
  • On Wednesday, July 17, Dr. Neil Cashman delivered data from ProMIS' preclinical program for ALS.
  • AAIC is the largest, most influential international meeting focused on advancing dementia science.
  • ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.

ProMIS Neurosciences to Present Data at 2019 Alzheimer's Association International Conference

Retrieved on: 
Wednesday, July 10, 2019
Promis, Promis, Cashman, AAIC, TARDBP, Slide

AAIC isthe largest, most influential international meeting focused on advancing dementia science.

Key Points: 
  • AAIC isthe largest, most influential international meeting focused on advancing dementia science.
  • Dr. Kaplan's slide presentation will be available on the company's website immediately following the presentation.
  • ProMIS' Chief Science Officer Dr. Neil Cashman will deliver the poster (#33496), "The Pathological Interactome of Tdp-43 Includes Human Wildtype SOD1" on Wednesday, July 17, 2019 in South Hall GH.
  • ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.